SCHEMBL3152149

SCHEMBL3152149

C[N+](C)(C)CCOc1ccc(C(=O)[O-])cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
ESR1 P03372 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 2/20 0.49
GAA P10253 1/20 0.49
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
KDM7A Q6ZMT4 1/20 0.47
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA10 Q9GZZ6 1/20 0.46
CHRNA9 Q9UGM1 1/20 0.46
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetrimonium SCHEMBL22396363 0.85 TP53 (0.60) GAATP53TSHR
SCHEMBL3152156 0.84 PKM (0.65) ESR1L3MBTL1PKMMAPK1TP53
SCHEMBL16418454 0.81 ESR1 (0.66) ESR1L3MBTL1MAPTGAABCHE
SCHEMBL3138707 0.81 MAPT (0.77) CA1CA2ESR1L3MBTL1MAPT
SCHEMBL11052789 0.80 TP53 (0.62) CA1CA2L3MBTL1GAATP53
Bromide SCHEMBL16414995 0.79 ESR1 (0.64) ESR1L3MBTL1MAPTGAABCHE
SCHEMBL3139692 0.78 TDP1 (0.61) CA1CA2ESR1L3MBTL1MAPT
Bicarbonate SCHEMBL9647641 0.78 CA1 (0.44) CA1CA2ESR1L3MBTL1CHRNB4
SCHEMBL12114038 0.78 ESR1 (0.48) ESR1L3MBTL1MAPTGAABCHE
Terephthalic Acid SCHEMBL30148140 0.77 MEN1 (0.48) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687546-B2 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease ACTIVUS PHARMA CO., LTD. (JP) 2010-03-30 US disclosed
US-20080269345-A1 Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease DAINIPPON INK AND CHEMICALS, INC. (JP) 2008-10-30 US disclosed
EP-1736464-A1 QUATERNARY AMMONIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, THERAPEUTIC AGENT FOR CEREBROVASCULAR DISORDER, AND THERAPEUTIC AGENT FOR HEART DISEASE Dainippon Ink and Chemicals, Incorporated (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269345-A1 Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease HRH4, KCNH3, ARGLU1 CA1 278/4885CA2 138/4885ESR1 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.